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Abstract The safety, efﬁcacy and long term clinical
beneﬁts of renal artery revascularization by stenting are
still a matter of debate. The aim of our study was to deﬁne
the safety and efﬁcacy of renal artery stenting with the
Tsunami peripheral stent (Terumo Corporation, Tokyo,
Japan). The ODORI was a prospective, multicentre registry
which enrolled 251 consecutive patients, (276 renal arter-
ies) in 36 centres across Europe. The primary endpoint was
acute procedural success deﬁned as\30% residual stenosis
after stent placement. Secondary endpoints included major
adverse events, blood pressure control, serum creatinine
level, and target lesion revascularization (TLR) at 6 and
12 months. Patients were 70 ± 10 years old, 59% were
male, 33% had diabetes, and 96% hypertension. The main
indications for renal stent implantation were hypertension
in 83% and renal salvage in 39%. Direct stent implantation
was performed in 76% of the cases. Acute success rate was
100% with residual stenosis of 2.5 ± 5.4%. Systolic/dia-
stolic blood pressure decreased from a mean of 171/89 at
baseline to 142/78 mmHg at 6 months (p \0.0001 vs.
baseline), and 141/80 mmHg at 12 months (p\0.0001 vs.
baseline). Mean serum creatinine concentration did not
change signiﬁcantly in the total population. However, there
was signiﬁcant improvement in the highest tercile (from
283 lmol/l at baseline to 205 and 209 lmol/l at 6 and
12 months respectively). At 12-months, rates of restenosis
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DOI 10.1007/s00270-009-9733-1and TLR were 6.6 and 0.8% respectively. The 12 month
cumulative rate of all major clinical adverse events was
6.4% while the rate of device or procedure related events
was 2.4%. In hypertensive patients with atherosclerotic
renal artery stenosis Tsunami peripheral balloon-expand-
able stent provides a safe revascularization strategy, with a
potential beneﬁcial impact on hypertension control and
renal function in the highest risk patients.
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Introduction
Atherosclerotic renal artery stenosis (RAS) is a common
condition that may lead to hypertension, progressive renal
dysfunction and cardiovascular morbidity [1]. It frequently,
in up to 40% of patients, accompanies coronary artery and
lower limb atherosclerotic disease [2, 3].
There is still controversy on the clinical efﬁcacy of
endovascular therapy of RAS. The randomized trials of
balloon angioplasty or stenting for renal artery stenosis
compared with medical therapy alone could not show
apparent advantage of this type of therapy. Some of those
trials were limited by enrollment of small number of
patients, frequent crossover from medical to interventional
therapy compromising the intention-to-treat results, or
selection of patients that are not expected to show clear
beneﬁt [4–7]. The preliminary results of ASTRAL [8] trial
also showed ambiguous ﬁndings related to incremental
value of revascularization in addition to medical therapy
alone. Publication of this study and anticipated results of
CORAL trial are expected to shed more light to this con-
troversial issue.
Concerning revascularization strategy several studies
demonstrated equal or better hemodynamic result for stents
as compared with balloon angioplasty with higher success
rate and long-term patency [9–13]. Currently the use of
stents is the preferred treatment option for patients
requiring revascularization of RAS, mainly for ostial
lesions which tend to recoil due to their elastic nature.
Theprimaryaimofthisprospective,multicentre,ODORI
registry was to assess the immediate technical success, and
impactonbloodpressureandrenalfunctionuptooneyear,in
a large cohort of patients undergoing Tsunami peripheral
stent placement.
Methods
Inclusion/Exclusion Criteria
Patients, at least 18 years old, with atherosclerotic renal
artery stenosis of more than 50%, judged by the clinicians
as indicated for renal revascularization, were enrolled in
the study.
Excluded were patients with ﬁbromuscular dysplasia,
total occlusion, spontaneous dissection or in-stent reste-
nosis of renal artery, stenosis of a transplant or bypass graft
anastomosis, aneurysm of abdominal aorta larger than
45 mm in diameter, current pregnancy, and contraindica-
tion to contrast media, aspirin, thienopyridines, heparin or
any other therapy as required for elective intervention.
The ODORI registry was conducted in 36 institutions
(listed in Appendix 1) from February 2005 to February
2007. The study was carried out according to the Decla-
ration of Helsinki, and respecting all country-speciﬁc reg-
ulatory requirements. The protocol was reviewed and
approved by the ethics committee of participating hospitals
and written informed consent was obtained from the
patients prior to stent implantation.
Tsunami Peripheral Stent
Tsunami peripheral stent is a stainless-steel, laser cut,
open-cells stent mounted on a rapid exchange delivery
balloon catheter compatible with 0.01400 and 0.01800
guidewire. The stent design comprises 12 cells with a triple
link in diameters 5 and 6 mm, and 14 cells with quadruple
link in 7 mm diameter, with a strut thickness of 0.007100
(0.18 mm). All stents are compatible with 5 Fr long sheath
or 6 Fr guiding catheter. Stents were available in diameters
of 5, 6 and 7 mm and in lengths of 12 and 18 mm. Fig. 1.
Procedure
Stent implantation was performed in a standard fashion via
retrograde femoral, brachial or radial approach. Tsunami
peripheral stent was implanted at recommended pressure
and correct stent size was selected based on visual
assessment.
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123Peri-procedural and post-procedure anticoagulant and
antiplatelet therapy were according to the routine hospital
practice and were left to the discretion of treating
physician.
In the initial protocol patient follow-up included visits at
30 days and visit or telephone follow-up at 6 months. The
protocol was later amended to include 12 months follow-
up by either hospital visit or telephone follow-up. At that
time 12 centres enrolling total of 134 patients agreed to
extend patients follow-up. At follow-up special attention
was paid to adverse event surveillance along with a
detailed questionnaire about concurrent antihypertensive
medications and self measured blood pressure. If the
patient visited hospital blood samples were drawn for
routine laboratory screening, and measurement of resting
systolic and diastolic blood pressure were performed. At
six and 12 months duplex ultrasonography of the renal
artery and stent was conducted to assess patency.
A conﬁrmatory angiogram was recommended if duplex
ultrasound suggested restenosis.
Study Deﬁnitions and Endpoints
The deﬁnitions in this study are based on Guidelines for the
Reporting of Renal Artery Revascularization in Clinical
Trials [14].
Primary endpoint of the study was acute technical suc-
cess deﬁned as angiographic residual diameter stenosis
lower than 30%, calculated as the ratio of the residual
target lesion lumen diameter to the diameter of the refer-
ence segment of the artery using visual estimates.
Secondary endpoints included major complications
within 48 h after stent implantation, improvement in blood
pressure, number of medications and serum creatinine level
at 6 and 12 months, restenosis deﬁned as more than 50%
diameter stenosis at 6 and 12 months (assessed by ultra-
sound or angiography) and clinical patency rate at 6 and
12 months deﬁned as absence of clinical need for target
lesion revascularization (TLR).
Blood pressure outcomes were deﬁned as follows:
• Cure—diastolic blood pressure B90 mmHg and sys-
tolic blood pressure B140 mmHg, in patients without
antihypertensive medications.
• Improvement—diastolic blood pressure B90 mmHg
and/or systolic blood pressure B140 mmHg on the
same or reduced number of medications or a reduction
in diastolic blood pressure by at least 15 mmHg with
the same or a reduced number of medications.
• Failure—no change or inability to meet these criteria
for cure or improvement.
• Beneﬁt—cure or improvement
Renal function outcomes were deﬁned as follows:
• Improvement of renal function, deﬁned as increase of
20% or more from baseline estimated glomerular ﬁltra-
tion rate (e-GFR)
• Worsening of the renal function, deﬁned as decrease of
20% or more from baseline e-GFR
• Stabilization of the renal function deﬁned as absence of
deterioration.
The duplex criteria for restenosis were according to the
local preferences and deﬁned as peak systolic velocity
(PSV) [180 cm/s and [3.5:1 renal artery to aortic peak
systolic velocity ratio. Only successful duplex recordings
were considered for restenosis assessment.
Major Clinical Adverse Events
Major clinical adverse events (MACE) are deﬁned as an
event resulting in an additional procedure, unplanned
treatment, prolonged hospitalization, transfusion, or death
(e.g., arterial thrombosis treated with thrombolytic therapy,
renal failure, femoral pseudoaneurysm, or hematoma
requiring surgical exploration or other directed therapy,
retroperitoneal bleeding). Deaths occurring within 30 days
of the renal stent procedure, or during the index hospital-
ization are considered as a procedure-related mortality.
Study Organization
All data were entered electronically on predeﬁned case
report forms. Data were stored in a central database of
KIKA Medical, Paris, France. Queries were continuously
generated throughout the study and sent to the investigators
for resolution.
All major adverse events were assessed by an indepen-
dent clinical events monitor.
Fig. 1 Expanded Tsunami peripheral stent
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123Statistical Design and Analysis
Analytical Plan
This was an observational, non-randomized study. There-
fore, the statistical analysis was based on descriptive sta-
tistical techniques. Categorical variables are presented as a
rate with its 95% exact conﬁdence interval, whenever
appropriate. Continuous variables are presented as means
±1 standard deviation with their 95% conﬁdence interval,
whenever appropriate. To assess the risk factors contrib-
uting to the endpoints, Student’s t-test was used for con-
tinuous variables and Fisher exact test for dichotomical
variables. The analyses were made on either patient (age,
gender, diabetes mellitus, hypertension, renal function) or
lesion related (lesion length, reference diameter) parame-
ters and the results are presented separately for entire
population and stratiﬁed per risk groups according to the
baseline values. To more correctly assess changes in some
of the most relevant parameters and to avoid bias in follow-
up compliance, the calculations are also performed sepa-
rately for matched data at baseline and follow-up using
paired t-test or McNemar’s test. This analysis took into
consideration only baseline values of patients which were
available for follow-up at corresponding time points (6 or
12 months).
All tests were considered statistically signiﬁcant when
p\0.05 (alpha was set at 0.05).
Results
The main baseline characteristics are given in Table 1.
Patients were on average 70 years old, 59% male, with 49%
current or previous smokers, 64% treated for lipid abnor-
malities, 96% treated for hypertension and 33% diabetic
patients. Only 25% of patients had systolic blood pressure
below 150 mmHg, while 51% of patients had serum creati-
nine level at or above 120lmol/l. The estimated glomerular
ﬁltration rate (GFR) lower than 30 ml/min/1.73 m
2 was
detected in 23% of the patients.
The main indications for the intervention (categories not
mutually exclusive) were hypertension (83%), renal sal-
vage (39%) and cardiac indications (19%). Hypertension
combined with renal insufﬁciency was present in 25.5%,
while simultaneous presence of hypertension, renal insuf-
ﬁciency and cardiac insufﬁciency was diagnosed in 8.4%
of the treated patients. Most of the patients referred for
hypertension were treated for refractory hypertension.
Patients indicated for treatment for renal salvage (94
patients) were diagnosed as renal dysfunction not attrib-
utable to another cause (57), renal failure after ACE
inhibitors (13) and sudden unexplained worsening of renal
function (24).
During the procedure 28.7% of the patients received
dual antiplatelet therapy (aspirin and clopidogrel), 43.4%
and 9.6% respectively, aspirin and clopidogrel alone, while
18.3% of the patients were treated without antiplatelet
therapy.
In total 277 Tsunami peripheral stents were used to treat
276 lesions in 221 patients with single unilateral lesions
and in 28 patients with bilateral lesions. Single functioning
kidney was present in 30 (12%) patients. The reason for
stenting was primary stenting in 87%, recoil after angio-
plasty in 8.3%, and residual pressure gradient or ﬂow
limiting dissection in 2.5% of the cases. The baseline
characteristics of the treated arteries are given in Table 2.
Renal artery stenosis was evenly distributed between right
and left renal arteries, being in an ostial position in 81.2%.
Mean reference diameter was 5.9 ± 0.7 mm. The mean
percent diameter stenosis of the target vessel (by angiog-
raphy) was 82.3 ± 9.8% before procedure and 2.5 ± 5.4%
post stent implantation.
The primary endpoint of the study, the acute technical
success (residual diameter stenosis\30%) was obtained in
100% of the lesions. Technical features of the stent were
satisfactory with good ﬂuoroscopic visibility, allowing
precise positioning particularly in ostial lesions. Direct
stenting was performed in 76% of lesions. Massive calci-
ﬁcation was present in 20% of the lesions, but 76% of those
lesions were also treated by direct stenting. In two patients
an additional stent placement was required in the same
Table 1 Baseline patient characteristics
Patient characteristic
Number of patients enrolled 251
Age (years) 70.0 ± 10.4
Sex (M) 58.6%
Diabetes 32.9%
Smoking history 49.0%
Hypercholesterolemia 64.2%
Pulmonary edema history 4.8%
Hypertension 95.6%
Systolic blood pressure (mmHg) 171 ± 26
Diastolic blood pressure (mmHg) 89 ± 14
Creatinine (lmol/l) 153 ± 123
Baseline estimated GFR (ml/min/1.73m
2)* 54.3 ± 33.3
e-GFR C60 33.0%
e-GFR C30\60 44.8%
e-GFR\30 22.2%
Numbers are means ± standard deviation, or percentages
* Estimated glomerular ﬁltration rate using Cockcroft–Gault formula
[12]
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123session, one for dissection and one due to distal migration
of the ﬁrst implanted stent in a very obese patient.
One peri-procedural stent thrombosis that was success-
fully resolved by thrombolysis was the only major clinical
adverse event during index hospitalization (Table 3). The
patient did not receive clopidogrel during the procedure.
There were 6 additional procedural complications: three
minor dissections, one partial embolization and two fem-
oral hematomas not requiring transfusion or surgery. All
complications were resolved without sequelae and none
required prolonged hospital stay.
One patient died in the ﬁrst month after stent implan-
tation due to pulmonary artery embolism, accounting for a
0.5% (1/251) 1-month mortality.
Six and 12-Months Follow-Up
At six months 164 patients were available for assessment.
Four patients died, two from cardiac causes, one from renal
failure and one from gastrointestinal causes. One patient
underwent percutaneous revascularization of the target
lesion due to an in-stent restenosis of more than 70%
assessed by angiography.
No other serious adverse events were reported (Table 3).
At 12 months follow-up 111 out of 134 patients con-
sented for extended follow-up were available for assess-
ment. Seven more patients died, two each from renal
failure and pneumonia and one each from pulmonary
edema, cardiac failure and unknown causes. One more
patient had repeat procedure for in-stent restenosis (76%
stenosis by angiography).
Table 4 presents the impact of renal artery stenting on
systolic and diastolic blood pressure. Systolic/diastolic
blood pressure decreased from a mean of 171 /89 mmHg at
baseline to 142/78 mmHg at 6 months (p \0.0001 vs.
baseline), and 141/ 80 mmHg at 12 months (p\0.0001 vs.
baseline).Pulsepressuredecreasedsigniﬁcantly(p\0.001)
at both 6 and 12-months follow-up. Mean number of medi-
cations per patient at 6 months decreased from 2.63 ± 0.95
to 2.23 ± 1.15 (p = 0.002) and at 12 months from
2.67 ± 0.95to2.45 ± 1.23(p = NS)(Fig. 2).Thebaseline
data in this analysis were taken only for corresponding
patients for whom 6 and/or 12 months follow-up were
available.
In the overall population, the mean serum creatinine did
not change signiﬁcantly (153 ± 123 lmol/l at baseline and
163 ± 127 lmol/l at 12 months) (Table 5). The mean
estimated glomerular ﬁltration rate at follow-up was
mainly unchanged or slightly worsened in patients with
higher baseline values, while it signiﬁcantly improved in
patients with values below 30 ml/min/1.73 m
2 before
procedure (Table 6).
Table 3 In-hospital and long-term major adverse events
Event Number %
Up to 1 month follow-up
Death (total) 1 0.4
Cardiovascular death 1 0.4
Stent thrombosis 1 0.4
Total major clinical events 2 0.8
From 1 month to 1 year follow-up
Death (total) 11 4.4
Cardiovascular death 4 1.6
Death due to renal failure 3 1.2
Pulmonary death 1 0.4
MI 1 0.4
Target lesion revascularization 2 0.8
Total Events up to 1 year
Total major adverse events up to 1 year follow-up 16 6.4
Total number of patients with major adverse events up
to 1 year follow-up
15 6.0
Total major adverse events up to 1 year follow-up
related to device or procedure
6 2.4
Table 2 Lesion and procedure characteristics
Lesions characteristic
Number of arteries treated per subject
1 artery 88.8%
2 arteries 11.2%
Side artery/ kidney treated
Left 52.9%
Right 47.1%
Location artery treated
Ostium 81.2%
Trunk 18.8%
Heavily calciﬁed lesions 20.0%
RVD 5.9 ± 0.7
Diameter artery stenosis (%) 82.3 ± 9.8
[50\70% 16 (5.8%)
C70\80% 63 (29%)
C80–100% 195 (71%)
Procedure characteristics
Number stents used 277
Mean stents per patient 1.1 ± 0.3
Mean Stent diameter (mm) 5.9 ± 0.65
Mean Stent length (mm) 14.9 ± 3.75
Direct stenting 75.8%
Direct stenting in heavily calciﬁed lesions 75.6%
Mean deployment pressure (atm) 10.5 ± 2.6
Technical success 100%
Number are percentages (number of total), or means ± SD
RVD reference vessel diameter
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123Duplex Ultrasound Results
Successful duplex ultrasonography at six months was
performed on 91 arteries and two (2.2%) arteries showed
restenosis of more than 50%. One patient underwent
angiography and TLR for symptomatic 76% restenosis.
The other was a patient that had undergone bilateral
stenting at baseline with embolic complication to the left
kidney. The 6 month duplex control showed a widely
patent right and totally occluded left renal artery. Because
the patient was asymptomatic no additional treatment was
performed.
At 12 months restenosis was detected in 3 out of 69
(4.3%) arteries assessed. Two patients were asymptomatic
and no angiography was performed, while a third patient
had angiographic conﬁrmation of restenosis (76%) and
underwent successful TLR by a cutting balloon.
Discussion
Our large, multicentre evaluation showed that the use of
Tsunami peripheral stent for the treatment of renal artery
stenosis is a safe and effective therapy. Signiﬁcant
improvement or stabilization of hypertension at 6 and
12 months after the procedure has been observed. Fur-
thermore, 100% procedural success with no major peri-
procedural complications indicates that renal artery stent-
ing with this, newly developed, device is safe.
Catheter-based therapy for symptomatic, hemodynami-
cally signiﬁcant, atherosclerotic RAS has become the
preferred method of revascularization. Balloon angioplasty
has been the traditional treatment of choice, but lately,
particularly for the treatment of ostial lesions, stents are
more frequently used. Despite the increased use of endo-
vascular therapy for renal artery stenosis the controversies
about the net beneﬁt of this treatment still exists [7, 8].
In our study stent placement signiﬁcantly reduced both
systolic and diastolic blood pressures at all time points as
compared to baseline. Almost three out of four patients
showed beneﬁt of treatment by improvement in hyperten-
sion control, ﬁndings comparable to previously reported
results [10–13]. Also the pulse pressure, frequently indi-
cated as an important predictor of mortality, showed sig-
niﬁcant improvement at 6 and 12 months [15]. However,
despite the general positive effect of renal artery revascu-
larization on blood pressure, only a small group of patients
(5%) showed cure of hypertension. This ﬁnding conﬁrms
that an association between renal artery stenosis and
renovascular hypertension is a complex and multifactorial
process, and that further studies are needed to identify
patients who will beneﬁt from percutaneous treatment, and
to deﬁne the optimal timing for the indicated intervention.
The improvement in renal function was not as apparent
as the improvement in hypertension control, a ﬁnding
reported in many studies [14–17]. However, considering
the population included in our study and common knowl-
edge that renal impairment is a progressive disease which
markedly reduces life expectancy and quality of life, par-
ticularly in patients who become dependent on dialysis, any
stabilization of renal dysfunction and disease progression
should be regarded as a beneﬁcial outcome. According to
Table 4 Changes in mean systolic and diastolic blood pressure over follow-up
Blood pressure Baseline 6 months p 12 months p
Systolic BP 171 ± 26 142 ± 18 \.0001 141 ± 17 \.0001
Diastolic BP 89 ± 14 78 ± 10 \.0001 80 ± 9 \.0001
Hypertension cure (%)
a 4.9% 5.7%
Hypertension improvement (%)
b 77.4% 70.8%
Pulse pressure (mmHg) 85.02 ± 22.08 63.36 ± 16.15 \0.001
c 61.34 ± 14.42 \0.001
c
a Cure = diastolic blood pressure B90 mmHg and systolic blood pressure B140 mmHg, off antihypertensive medications
b Improvement = diastolic blood pressure B90 mmHg and/or systolic blood pressure B140 mmHg on the same or reduced number of medi-
cations or a reduction in diastolic blood pressure by at least 15 mmHg with the same or a reduced number of medications
c Paired student’s t-test
2,45 2,67 2,63 2,23**
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*Only patients with the data available at baseline and respective follow-up are included. 
**p=0.002, Paired Student's t-Test.  
Fig. 2 Mean number of antihypertensive medications at 6 and
12 months for matched patients. Only patients with the data available
at baseline and respective follow-up are included. ** p = 0.002,
paired student’s t-test
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123the American Heart Association guidelines, a slowed
decline in renal function is sufﬁcient to support the claim
that renal artery angioplasty is beneﬁcial [14]. In our study
the best results were observed in patients with the lowest
baseline e-GFR. Unfortunately the number of patients in
this subgroup with long-term follow-up was relatively
small, therefore, drawing any conclusion from this ﬁnding
would be inappropriate. Our results are similar to some of
previous reports [16–18], however, Blum et al. [12] and
White et al. [9] found no signiﬁcant change in creatinine,
independent of baseline renal function. Those discrepant
ﬁndings may be a result of small sample size or the
inclusion of stenoses from 50% to 70% which are not
hemodynamically relevant and can therefore not cause
ischemic nephropathy [19]. In our series of patients,
however, only 16 patients (5.8%) had stenosis between
50% and 70%, bringing further controversies to this sub-
ject. Moreover, slight deterioration in renal function
observed in patients with highest e-GFR at baseline is
difﬁcult to explain. It could be related to the natural pro-
gression of the disease or to a certain degree of cholesterol
embolism that may put patients at risk of renal function
deterioration.
The assessment of renal function and signiﬁcance of
RAS are also not well deﬁned. As recently indicated by
Drieghe et al. using the current criteria for RAS, a diameter
Table 5 Estimated glomerular
ﬁltration rate at follow-up (ml/
min/1.73m
2)
Estimated glomerular ﬁltration
rate using Cockcroft-Gault
formula [14]
a p\0.001 (by Mc Nemar test)
Improvement = Increase of e-
GFR by 20% versus baseline
Worsening = Decrease of e-
GFR by 20% versus baseline
Stabilization = No worsening
Estimated GFR Baseline
N = 251
6 months
FUP N = 154
12 months
FUP N = 97
Baseline GFR MILD e-GFR C 60
N = 82 N = 45 N = 29
Mean ± SD 90.32 ± 36.59 85.55 ± 37.24 62.03 ± 26.23
Improvement 8.89% 3.45%
Stabilization 75.56% 58.62%
Worsening 15.56% 37.93%
Baseline e-GFR MODERATE e-GFR C30\60
N = 111 N = 68 N = 48
Mean ±SD 45.37 ± 8.68 49.82 ± 26.87 47.33 ± 15.22
Improvement 27.94% 22.92%
Stabilization 54.41% 62.50%
Worsening 17.65% 14.58%
Baseline GFR SEVERE e-GFR\30
N = 55 N = 41 N = 20
Mean ±SD 20.61 ± 7.31 35.40 ± 25.46
a 36.32 ± 22.84
Improvement 51.22% 50.00%
Stabilization 39.02% 50.00%
Worsening 9.76% 0.00%
Overall population
N = 248 N = 154 N = 97
Mean ± SD 54.74 ± 34.69 56.42 ± 35.66 49.46 ± 22.43
Improvement 28.57% 22.68%
Stabilization 56.49% 58.76%
Worsening 14.94% 18.56%
Table 6 Changes in mean estimated GFR values in subgroup of patients stratiﬁed according to baseline values
Baseline value
(ml/min/1.73 m
2)
Post
procedure
p Value* 30 Days p Value* 6 months p Value* 12 months p Value*
C60 -7.6 0.02 -8.2 0.12 -10.2 0.13 -24.9 0.02
C30\60 ?3.4 0.01 ?14.1 0.01 ?3.9 0.21 ?1.1 0.54
C15\30 ?8.4 0.06 ?5.3 0.02 ?9.7 \0.001 ?12.9 0.04
\15 ?7.6 0.26 ?33.7 0.04 ?32. 8 0.18 ?23.9 0.18
‘‘?’’ indicates improved creatinine clearance, while ‘‘-’’ indicates worsening. * Paired
Student’s t-test. Only patients with the data available at baseline and respective follow-up are included
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123stenosis [50% by angiography falsely identiﬁes a renal
stenosis as signiﬁcant in approximately 38% of cases and
ultrasound does so in approximately 55% of cases [20].
This indicates that the commonly accepted criteria of sig-
niﬁcant RAS overestimate the actual severity of the lesion.
It is likely, therefore, that in our study as well as in the
other studies that have investigated the usefulness of renal
revascularization for the treatment of renovascular hyper-
tension and renal disease progression, a sizable proportion
of patients with hemodynamically non-signiﬁcant stenosis
might have been included. Since, in these patients, no
beneﬁt of renal artery stenting can be expected (as they had
arterial hypertension or renal function impairment of other
etiologies), their inclusion in these trials has most probably
hazed the beneﬁts of renal angioplasty over medical
treatment.
Technical Characteristics
The procedural performance of Tsunami stent in our study
was good without occurrence of in-hospital deaths, artery
perforation or rupture, or other major complications. As
expected, a low crossing proﬁle allowed direct stenting in
more than 75% of lesions, including severely calciﬁed
lesions, reducing contrast dose, and radiation load and also
procedure time. This ﬁnding compares favorably with other
low proﬁle platforms [21].
Although large number of patients in our study did
not undergo ultrasound evaluation, the 6.6% cumulative
incidence of restenosis (2/91 at 6 months and 3/64 at
12 months) is comparable with ﬁndings in other contem-
porary trials or meta-analyses [10, 21–23]
High procedural success and relatively low frequency of
adverse events in our study may indicate that reﬁnement of
the devices and techniques for renal artery revasculariza-
tion, along with careful patient selection could possible
improve the clinical outcome after endovascular revascu-
larization of RAS. Our aims must therefore be to improve
primary and secondary prevention, achieve an earlier
diagnosis, and, when indicated, appropriately treat occlu-
sive renal disease.
Study Limitations
Our study has several limitations, the major being lack of
control group which would allow the assessment of the
value of the renal artery revascularization. A relatively low
follow-up rate reduced the possibility of identifying
patients at risk and patients expected to show beneﬁt. This
registry did not mandate follow-up by hospital visit and
hence the number of ultrasound assessments is small which
along with absence of an independent core-lab prevents a
clear conclusion related to restenosis.
Conclusion
The ﬁndings of our study indicate that primary stent place-
ment in atherosclerotic RAS is safe procedure which might
be beneﬁcial for improved control of hypertension and sta-
bilization of renal function in patients on highest risk. Good
technical success, low complication rate, low restenosis and
TLR rate indicate that this stent platform could be a useful
tool for further randomized controlled trials.
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